Dr. Arend Discusses Targets in Endometrial Cancer

Rebecca Arend, MD
Published: Tuesday, Aug 01, 2017



Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.

There was a gynecologic study that showed that the combination of the mTOR inhibitor everolimus (Afinitor) and letrozole provided prolonged benefit in a patient with an mTOR mutation.

Regimens of EZH2 inhibitors in patients with ARID1A mutations, as well as MEK inhibitors, are also in the pipeline and are worth consideration, says Arend.
 


Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.

There was a gynecologic study that showed that the combination of the mTOR inhibitor everolimus (Afinitor) and letrozole provided prolonged benefit in a patient with an mTOR mutation.

Regimens of EZH2 inhibitors in patients with ARID1A mutations, as well as MEK inhibitors, are also in the pipeline and are worth consideration, says Arend.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x